Welcome to Precision Vaccinations News
WEB1 day ago · Can Dengue Outbreaks Be StoppedDengue in Los Angeles, Miami, New York, Puerto Rico, Texas in 2024. 5th MERS Cases Confirmed in the Kingdom of Saudi ArabiaMERS vaccine candidates are conducting clinical trials in 2024. Californians Confront Dengue and West Nile Virus OutbreaksDengue and West Nile cases reported in Los Angeles and Central Valley ...
mRNA-Based Flu Shot Focuses on Improving Performance in …
WEBApr 4, 2024 · As influenza vaccine producers prepare for the 2024 - 2025 flu season, innovative vaccine candidates are progressing in clinical research, focused on enhancing efficacy and safety. CureVac N.V. today announced interim data from an ongoing Phase 2 study, which is part of the combined Phase 1/2 study …
HSV Treatment Readies for Approval — Precision Vaccinations News
WEBA recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV). As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.
2024–25 Influenza Vaccine Recommendations Updated
WEBAug 29, 2024 · The U.S. Centers for Disease Control and Prevention (CDC) recently updated its annual vaccination recommendations for the 2024-25 flu season, noting two fundamental changes. On August 29, 2024, the CDC stated (73(5);1–25) the primary updates include the following two topics: the composition of 2024–25 seasonal influenza vaccines with the return to trivalent vaccines and updated ...
Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States. GlaxoSmithKline plc. (GSK), known for its extensive range of vaccines for various conditions, including RSV, meningitis, and shingles, is conducting an innovative study ...
$3.3 Million NIH Grant for Developing Enhanced Seasonal …
WEB3 days ago · Orlance, Inc. today announced it was awarded the National Institutions of Health (NIH) Fast Track Small Business Innovation Research (SBIR) grant to develop an Enhanced Seasonal Influenza Vaccine. This vaccine is intended to provide better protection against disease even in years when predicted vs. actual circulating strains are highly mismatched. The award includes $300,000 for Phase 1, with ...
Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
US FDA Says Updated Protein-Based COVID-19 Vaccine Protects …
WEBAug 30, 2024 · The U.S. Food and Drug Administration today announced it granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating SARS-CoV-2 virus variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. Novavax's updated COVID-19 vaccine targets the "parent ...
Vaccine News — Precision Vaccinations News
WEBOct 1, 2024 · According to survey results published in a Morbidity and Mortality Weekly Report (73 (38);837–843) on September 26, 2024, 33% of eligible pregnant women reported receiving an RSV vaccination. Most vaccinated women (54.1%) reported receiving the vaccine at an obstetrician or gynecologist's office.
Chronic Hepatitis B Treatment Receives U.S. FDA Fast Track …
WEBFeb 13, 2024 · GSK plc announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). GSK said on February 12, 2024, Bepirovirsen is the only single agent in phase III development that has shown the potential to achieve clinically meaningful functional cure ...
- Some results have been removed